Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with irreversible electroporation and intratumoral CpG for metastatic pancreatic cancer
NL-OMON55025Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nivolumab and tilsotolimod in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (3 arms), sponsored by Vrije University Medical Center. Primary endpoint: Primary safety endpoint. Started Dec 2020; status: recruiting.
02
Drugs
nivolumabtilsotolimod
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON55025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55025.